Kiora Pharmaceuticals (KPRX) Other Non Operating Income (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Other Non Operating Income came in at -$47127.0 in Q1 2026, down 189.96% YoY from $52387.3 in Q1 2025, and down 76.14% on a QoQ basis from -$26755.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Other Non Operating Income (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 8 years of Other Non Operating Income data on file, last reported at -$47127.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 189.96% year-over-year to -$47127.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$191146.0 (down 10997.72% YoY) and the FY2025 annual result came in at -$160272.0, down 714.7% from the prior year.
- Other Non Operating Income retreated to -$47127.0 in Q1 2026, from -$26755.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $105715.0 in Q3 2023 to a low of -$93556.0 in Q2 2025.
- A 5-year average of -$11412.9 and a median of -$19646.0 in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income surged 11182.28% — and 2025, when it plunged 396.03%.
- Tracing KPRX's Other Non Operating Income over 5 years: stood at -$19646.0 in 2022, then sank by 234.17% to -$65652.0 in 2023, then soared by 247.44% to $96797.0 in 2024, then sank by 127.64% to -$26755.0 in 2025, then sank by 76.14% to -$47127.0 in 2026.
- The last three Other Non Operating Income figures came in at -$47127.0 (Q1 2026), -$26755.0 (Q4 2025), and -$23708.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11,471.00 |
| Mar 31, 2026 | -47,127.00 |
| Dec 31, 2025 | -26,755.00 |
| Sep 30, 2025 | -23,708.00 |
| Jun 30, 2025 | -93,556.00 |
| Mar 31, 2025 | -16,253.00 |
| Dec 31, 2024 | 96,797.00 |
| Sep 30, 2024 | -59,929.00 |
| Jun 30, 2024 | -18,861.00 |
| Mar 31, 2024 | 8,066.00 |
| Dec 31, 2023 | -65,652.00 |
| Sep 30, 2023 | 105,715.00 |
| Jun 30, 2023 | -25,888.00 |
| Mar 31, 2023 | 14,666.00 |
| Dec 31, 2022 | -19,646.00 |
| Sep 30, 2022 | 937.00 |
| Dec 31, 2021 | -278,190.00 |
| Jun 30, 2021 | 278,190.00 |
| Dec 31, 2015 | 1.00 |
| Sep 30, 2015 | -1,987.00 |